Seattle Genetics

from Wikipedia, the free encyclopedia
Seattle Genetics, Inc.

logo
legal form Inc.
ISIN US8125781026
founding July 15, 1997
Seat Bothell , United StatesUnited StatesUnited States 
management Clay B. Siegall
Number of employees > 900
sales $ 654.7 million (2018)
Branch Biotechnology , pharmaceuticals
Website www.seattlegenetics.com

Seattle Genetics is a US biotechnology company that develops and markets therapies for the treatment of cancer based on monoclonal antibodies . Based in Bothell, Washington, a suburb of Seattle, the company makes chemoimmunoconjugates that use monoclonal antibodies to deliver cell-killing agents directly to cancer cells. They should spare the healthy cells and thereby reduce the toxic effect of chemotherapy and increase the effectiveness against the tumor.

history

Seattle Genetics was founded in 1997 by Clay Siegall. In March 2001 the company went public; the shares are traded on NASDAQ. In December 2016, the company had over 900 employees in the United States. In January 2018, the company announced it would buy Cascadian Therapeutics for $ 614 million.

Cooperations

Seattle Genetics is developing Enfortumab with Astellas Pharma , and Tisotumab with Genmab . In addition, there is Ladiratuzumab in development. Seattle Genetics has a collaboration agreement with Takeda Oncology to develop and commercialize brentuximab. Further agreements exist with AbbVie , Bayer AG , Celldex Therapeutics, Daiichi Sankyō , Genentech , GlaxoSmithKline , Pfizer and PSMA Development. There is also a development agreement with Agensys (a subsidiary of Astellas Pharma and Oxford BioTherapeutics).

Products

The company's products include brentuximab for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma . The product is approved for four indications in over 65 countries, including the United States, Canada, Japan and the European Union. Seattle Genetics is working with Takeda Pharmaceutical to expand the uses for brentuximab . Under the collaboration, Seattle Genetics owns the marketing rights for the United States and Canada, while Takeda has the rights for all other countries.

Brentuximab works in combination with monomethyl auristatin E (MMAE) and is used for cancer treatment based on monoclonal antibodies. In brentuximab, for example, the chimeric antibody anti-CD30 (cAC10) is linked to MMAE via a protease-cleavable compound. This chemoimmunoconjugate uses a compound that is stable in the bloodstream, but that MMAE releases upon contact with tumor cells that secrete CD30. This procedure should spare healthy cells and reduce the toxic effect of chemotherapy, while the effectiveness against tumor cells should be increased.

Developments include Vorsetuzumab for the treatment of kidney cancer and non-Hodgkin lymphoma , enfortumab for the treatment of bladder, breast, lung and pancreatic cancer, and denintuzumab for the treatment of haematopoietic tumors.

Individual evidence

  1. ^ A b Rob Wright: Seattle Genetics Legacy Of Partnering . In: Life Science Leader . February 13, 2018. Retrieved February 22, 2018.
  2. ↑ SA Transcripts: Seattle Genetics (SGEN) Q4 2016 Results - Earnings Call Transcript (en) . In: Seeking Alpha , February 10, 2017. Retrieved January 10, 2018. 
  3. ↑ Seattle Genetics aims to put drug on the front line of battling cancer (en) . In: The Seattle Times , December 17, 2016. Retrieved January 10, 2018. 
  4. ↑ https://www.genengnews.com/gen-news-highlights/seattle-genetics-to-acquire-cascadian-therapeutics-for-614m/81255441
  5. ^ Seattle Genetics Corporate Profile Reuters
  6. ↑ a b Brentuximab vedotin (SGN35) , ADC Review / Journal of Antibody-drug Conjugates
  7. ↑ Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study JCO June 20, 2012 Vol. 30 No. 18 2190-2196
  8. ↑ Brentuximab vedotin (ADCETRIS®) Clinical Trials , ADC Review / Journal of Antibody-drug Conjugates
  9. ↑ IMGT / mAb-DB SGN-75 Poiron, C. et al., JOBIM 2010, Paper 13 (2010).
  10. ↑ Enfortumab Vedotin (ASG-22ME, Formerly AGS-22M6E) Clinical trials ADC Review / Journal of Antibody-drug Conjugates; Retrieved February 18, 2015
  11. ↑ Anti-Nectin-4 monoclonal antibody-drug conjugate AGS-22M6E National Cancer Institute (NCI) Drug Dictionary